These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26881718)

  • 1. Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
    Mazerbourg S; Kuntz S; Grillier-Vuissoz I; Berthe A; Geoffroy M; Flament S; Bordessa A; Boisbrun M
    Curr Top Med Chem; 2016; 16(19):2115-24. PubMed ID: 26881718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New troglitazone derivatives devoid of PPARγ agonist activity display an increased antiproliferative effect in both hormone-dependent and hormone-independent breast cancer cell lines.
    Colin C; Salamone S; Grillier-Vuissoz I; Boisbrun M; Kuntz S; Lecomte J; Chapleur Y; Flament S
    Breast Cancer Res Treat; 2010 Nov; 124(1):101-10. PubMed ID: 20054646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo cytotoxicity of troglitazone in pancreatic cancer.
    Fujita M; Hasegawa A; Yamamori M; Okamura N
    J Exp Clin Cancer Res; 2017 Jul; 36(1):91. PubMed ID: 28673319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicity.
    Saha S; New LS; Ho HK; Chui WK; Chan EC
    Toxicol Lett; 2010 Feb; 192(2):141-9. PubMed ID: 19854250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of troglitazone derivatives as potent anti-proliferative agents: towards more active and less toxic compounds.
    Bordessa A; Colin-Cassin C; Grillier-Vuissoz I; Kuntz S; Mazerbourg S; Husson G; Vo M; Flament S; Martin H; Chapleur Y; Boisbrun M
    Eur J Med Chem; 2014 Aug; 83():129-40. PubMed ID: 24953030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of a retinoic acid receptor pathway by thiazolidinediones induces production of vascular endothelial growth factor/vascular permeability factor in OP9 adipocytes.
    Kotake D; Hirasawa N
    Eur J Pharmacol; 2013 May; 707(1-3):95-103. PubMed ID: 23542713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review.
    Masubuchi Y
    Drug Metab Pharmacokinet; 2006 Oct; 21(5):347-56. PubMed ID: 17072088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ERK activity enhances the cytotoxic effect of peroxisome proliferator-activated receptor γ (PPARγ) agonists in HeLa cells.
    Chang HK; Kim DS; Chae JJ; Kim M; Myong JP; Lee KH; Lee MW; Park TC
    Biochem Biophys Res Commun; 2017 Jan; 482(4):843-848. PubMed ID: 27888104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARγ-inactive Δ2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
    Colin-Cassin C; Yao X; Cerella C; Chbicheb S; Kuntz S; Mazerbourg S; Boisbrun M; Chapleur Y; Diederich M; Flament S; Grillier-Vuissoz I
    Mol Carcinog; 2015 May; 54(5):393-404. PubMed ID: 24293218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma- and ERK-dependent in human non-small lung cancer cells.
    Li M; Lee TW; Yim AP; Mok TS; Chen GG
    J Cell Physiol; 2006 Nov; 209(2):428-38. PubMed ID: 16883598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells.
    Yan KH; Yao CJ; Chang HY; Lai GM; Cheng AL; Chuang SE
    Mol Carcinog; 2010 Mar; 49(3):235-46. PubMed ID: 19908241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity of troglitazone through PPARγ-independent pathway and p38 MAPK pathway in renal cell carcinoma.
    Fujita M; Yagami T; Fujio M; Tohji C; Takase K; Yamamoto Y; Sawada K; Yamamori M; Okamura N
    Cancer Lett; 2011 Dec; 312(2):219-27. PubMed ID: 21903322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
    Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
    Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated troglitazone activates PPARgamma and inhibits vascular smooth muscle cell proliferation and proteoglycan synthesis.
    Little PJ; Ballinger ML; Survase S; Osman N; Ogru E; Geytenbeek S; Bruemmer D; Nigro J
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):274-9. PubMed ID: 18356692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of peroxisome proliferator-activated receptor-gamma ligand troglitazone on colon cancer cell growth].
    Koirala K; Wan YL; Liu YC; Wang X; Cui W; Wang CL; Chen HN; Wang HY; Zhu J
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 38(4):385-8. PubMed ID: 16892143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of new troglitazone derivatives: anti-proliferative activity in breast cancer cell lines and preliminary toxicological study.
    Salamone S; Colin C; Grillier-Vuissoz I; Kuntz S; Mazerbourg S; Flament S; Martin H; Richert L; Chapleur Y; Boisbrun M
    Eur J Med Chem; 2012 May; 51():206-15. PubMed ID: 22409968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
    Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
    Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone attenuates epidermal growth factor receptor signaling independently of peroxisome proliferator-activated receptor in PC-3 cells.
    Zhu H; Pan X; Qi H; Wang X; Hou S; Han B; Liu Z; Xu L
    Oncol Rep; 2011 Jan; 25(1):81-90. PubMed ID: 21109961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth.
    Li M; Lee TW; Mok TS; Warner TD; Yim AP; Chen GG
    J Cell Biochem; 2005 Nov; 96(4):760-74. PubMed ID: 16149072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line.
    Yang YC; Ho TC; Chen SL; Lai HY; Wu JY; Tsao YP
    BMC Cancer; 2007 Nov; 7():216. PubMed ID: 18021457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.